

Samuel H. Pepkowitz, MD, Medical Director  
345 Oyster Point Blvd  
South San Francisco, CA 94080 - Tel: (800) 777-0177

Patient Initials	DOB	Patient ID/Medical Record #	Gender	Monogram Accession # <b>12-160132</b>
Date Collected	Date Received	Date Reported	Mode	Report Status
Investigator			Specimen ID	
Comments				

INI	Drug		GENESEQ™	ASSESSMENT*	Comments
	Generic Name	Brand Name	Drug Resistance Associated Mutations Detected	Drug	
	Elvitegravir	Elvitegravir	None	EVG Sensitive	
	Raltegravir	Isentress	None	RAL Sensitive	

\* Assessment of drug susceptibility is based upon detected mutations and interpreted using an advanced proprietary algorithm (version 3).

\* **Mixtures** are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a ^ symbol.

### Summary of Mutations Observed

INI S17C, V72I, T112R/S, V113I, T125A, K188R, K211K/R, T218I, N222N/K, V234L, A265V, R269R/K

For more information on interpreting this report, please visit [www.MonogramHIV.com](http://www.MonogramHIV.com) or call Customer Service at 800-777-0177 between the hours of 6:30am to 5:00pm PT Monday through Friday.

GeneSeq HIV Integrase is a sequencing assay based on primer extension and chain termination that analyzes the complete integrase coding region in HIV-1. This assay meets the standards for performance characteristics and all other quality control and assurance requirements established by the Clinical Laboratory Improvement Amendments. This test is validated for testing specimens with HIV-1 viral loads equal to or above 500 copies/mL and should be interpreted only on such specimens. The results should not be used as the sole criteria for patient management. The results have been disclosed to you from confidential records protected by law and are not to be disclosed to unauthorized persons. Further disclosure of these results is prohibited without specific consent of the persons to whom it pertains, or as permitted by law.